Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Current Opinion in Pulmonary Medicine|May 24, 2014
Intrapleural minocycline pleurodesis for the treatment of primary spontaneous pneumothoraxJin-Shing Chen, Wing-Kai Chan, Pan-Chyr Yang
Contemporary Clinical Trials|May 3, 2011
Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in TaiwanLi-Jiuan Shen, Hua Chou, Chih-Fen Huang, et al.
Cancer Research|May 19, 2007
Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1Chi-Chung Wang, Meng-Feng Tsai, Ting-Hao Dai, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 20, 2024
Oral docetaxel plus encequidar - A pharmacokinetic model and evaluation against IV docetaxelDavid Wang, Chris Jackson, Noelyn Hung, et al.
Cancer Chemotherapy and Pharmacology|May 30, 2024
Oral docetaxel plus encequidar - a phase 1 clinical trialDavid Wang, Noelyn Hung, Tak Hung, et al.
Pharmaceutics|May 25, 2024
A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical StudyDavid Wang, Natalie Hughes-Medlicott, Lilian Klingler, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2003
Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled studyChung-Pin Li, Yee Chao, Kwan-Hwa Chi, et al.
Lancet (London, England)|March 16, 2013
Simple aspiration and drainage and intrapleural minocycline pleurodesis versus simple aspiration and drainage for the initial treatment of primary spontaneous pneumothorax: an open-label, parallel-group, prospective, randomised, controlled trialJin-Shing Chen, Wing-Kai Chan, Kung-Tsao Tsai, et al.
American Journal of Respiratory and Critical Care Medicine|December 22, 2007
TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancerChao-Chi Ho, Wei-Yu Liao, Cheng-Yi Wang, et al.
Pharmaceutics|October 27, 2022
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I ResultsJin-Bon Hong, Po-Yuan Wu, Albert Qin, et al.
Pageof 3